- Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
- Passage Bio to Participate in Upcoming Investor Conferences
- Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
- Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
- Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
- Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
- Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
More ▼
Key statistics
As of last trade Passage Bio Inc (PASG:NSQ) traded at 1.37, -23.74% below its 52-week high of 1.79, set on Mar 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.33 |
---|---|
High | 1.43 |
Low | 1.25 |
Bid | 1.36 |
Offer | 1.41 |
Previous close | 1.31 |
Average volume | 98.69k |
---|---|
Shares outstanding | 61.61m |
Free float | 61.31m |
P/E (TTM) | -- |
Market cap | 80.71m USD |
EPS (TTM) | -1.87 USD |
Data delayed at least 15 minutes, as of May 06 2024 15:42 BST.
More ▼